News
12 Health Care Stocks Moving In Friday's Pre-Market Session
26 Apr 24
Movers
Roth MKM Maintains Buy on Moleculin Biotech, Maintains $40 Price Target
12 Apr 24
News, Price Target, Analyst Ratings
12 Health Care Stocks Moving In Monday's After-Market Session
8 Apr 24
Movers
Maxim Group Maintains Buy on Moleculin Biotech, Lowers Price Target to $20
26 Mar 24
News, Price Target, Analyst Ratings
Moleculin Biotech Provided A Preliminary Update On Recent Clinical Activity And Expected Near Term Milestones For Its Lead Program MB-106 For The Treatment Of Acute Myeloid Leukemia
25 Mar 24
Biotech, News, Health Care, General
Moleculin Biotech FY23 EPS $(15.07) Vs $(15.22) YoY; As Of December 31, 2023, The Company Had Cash And Cash Equivalents Of $23.6M
22 Mar 24
Earnings, News
Earnings Scheduled For March 22, 2024
22 Mar 24
Earnings
A Preview Of Moleculin Biotech's Earnings
21 Mar 24
Earnings
Micron, Signet Jewelers And 3 Stocks To Watch Heading Into Wednesday
20 Mar 24
Earnings, News, Penny Stocks, Pre-Market Outlook, Markets, Trading Ideas
12 Health Care Stocks Moving In Tuesday's After-Market Session
19 Mar 24
Movers
12 Health Care Stocks Moving In Monday's After-Market Session
4 Mar 24
Movers
Press releases
Moleculin Biotech (NASDAQ:MBRX) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team
25 Apr 24
Biotech, News, Press Releases
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
18 Apr 24
Small Cap, Press Releases
Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties
10 Apr 24
Small Cap, Press Releases
Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity
27 Mar 24
Small Cap, Press Releases
Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML
27 Mar 24
Press Releases
Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
25 Mar 24
Press Releases
Moleculin Reports Full Year 2023 Financial Results
22 Mar 24
Earnings, Press Releases
Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcast
20 Mar 24
Small Cap, Press Releases
Moleculin Announces Reverse Stock Split
19 Mar 24
Small Cap, Stock Split, Press Releases